Sor102 _hot_ -A more modern target that regulates the expansion of Th17 lymphocytes, key drivers of chronic gut issues. ): A well-validated target in IBD that promotes systemic and local inflammation. Greater decreases in the and rectal bleeding. Developed by Sorriso Pharmaceuticals , SOR102 isn't just another drug; it’s a first-in-class designed to tackle inflammation from two angles simultaneously while remaining confined to the gastrointestinal tract. The Science: Dual Targeting in a Tablet Higher rates of and symptomatic response. Localized activity confirmed by minimal systemic drug levels in the blood. Why it Matters: Breaking the "Therapeutic Ceiling" |
|
A more modern target that regulates the expansion of Th17 lymphocytes, key drivers of chronic gut issues. ): A well-validated target in IBD that promotes systemic and local inflammation. Greater decreases in the and rectal bleeding. Developed by Sorriso Pharmaceuticals , SOR102 isn't just another drug; it’s a first-in-class designed to tackle inflammation from two angles simultaneously while remaining confined to the gastrointestinal tract. The Science: Dual Targeting in a Tablet Higher rates of and symptomatic response. Localized activity confirmed by minimal systemic drug levels in the blood. Why it Matters: Breaking the "Therapeutic Ceiling" |
|
|